Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Year
  • 1
    Language: English
    In: Translational andrology and urology, December 2018, Vol.7(Suppl 6), pp.S744-S746
    Keywords: Editorial;
    ISSN: 2223-4691
    ISSN: 22234683
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: The Journal of Urology, April 2018, Vol.199(4), pp.e697-e698
    Keywords: Medicine
    ISSN: 0022-5347
    E-ISSN: 1527-3792
    Source: ScienceDirect Journals (Elsevier)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: The Journal of Urology, April 2014, Vol.191(4), pp.898-906
    Description: Several large, randomized, controlled trials provide evidence that neoadjuvant chemotherapy improves the outcome of radical cystectomy for muscle invasive urothelial bladder cancer. We analyzed the designs, methods and observations of these trials to identify patient subgroups that appeared most likely to benefit. We also identified distinguishing features compared to groups that did not achieve improved outcomes. We analyzed initial and updated methods and results of the 4 main prospective trials of neoadjuvant chemotherapy (SWOG, Medical Research Council, and Nordic I and II) and subsequent meta-analyses. These series are the basis for advocating neoadjuvant chemotherapy in all patients with muscle invasive urothelial bladder cancer who undergo radical cystectomy. The greatest apparent benefit was seen in patients free of cancer at radical cystectomy (pT0). They had markedly improved overall and disease specific survival compared to patients with residual disease. However, improvements occurred regardless of whether there was down-staging from muscle invasive urothelial bladder cancer to pT0 after transurethral resection alone (controls) or after resection plus neoadjuvant chemotherapy. Thus, the major benefit of chemotherapy appeared to be that more patients achieved pT0. We also explored the study limitations that may have influenced outcomes and considered the potential for overtreatment in patients not likely to benefit from chemotherapy. Finally, we used risk stratification to create a decision tree model for selecting patients for neoadjuvant chemotherapy that could conceivably maximize oncologic outcome and minimize overtreatment. Patients with pT0 in the 4 main neoadjuvant chemotherapy trials and their subsequent meta-analyses experienced similar survival, far exceeding that in groups that did not achieve pT0. The benefit of neoadjuvant chemotherapy appears to be the larger number of cases than in the transurethral resection only group that were down-staged to pT0, suggesting that variables other than chemotherapy may have influenced outcomes. Therefore, strategies to selectively administer neoadjuvant chemotherapy to certain patients at risk have the potential to maintain improved bladder cancer outcomes while reducing overtreatment and its associated toxicity.
    Keywords: Urinary Bladder Neoplasms ; Neoadjuvant Therapy ; Drug Therapy ; Cystectomy ; Risk Assessment ; Medicine
    ISSN: 0022-5347
    E-ISSN: 1527-3792
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: Aktuelle Urologie, 2017, Vol.48(04)
    In: Aktuelle Urologie, 2017, Vol.48(04), pp.340-349
    Description: Eine perioperative Chemotherapie verbessert wahrscheinlich sowohl in einem neoadjuvanten als auch in einem adjuvanten Konzept das Überleben des Patienten. Damit ist sie ein integraler Teil der modernen Therapie von Patienten mit einem muskelinvasiven Harnblasenkarzinom. Jeder Patient, der für eine Cisplatin-basierte Chemotherapie geeignet ist, sollte in ein entsprechendes Konzept eingebunden werden. Standard sowohl in der perioperativen als auch in der palliativen Systemtherapie des Urothelkarzinoms sind Cisplatin-basierte Kombinationstherapien. Carboplatin stellt nur bei „unfitten“ Patienten in der palliativen Therapiesituation einen möglichen Ersatz dar, in der perioperativen Systemtherapie besitz es keinen Stellenwert. Im Falle eines Rezidivs nach einer palliativen Erstlinientherapie oder bei einem schnellen Progress nach perioperativer Therapie kann eine Zweitlinientherapie mit Vinflunin durchgeführt werden. Alternativ dazu können auch Taxane oder Taxan-basierte Kombinationen zum Einsatz kommen. Neue Therapiemöglichkeiten sind der Einsatz von Immuncheckpoint-Inhibitoren, welche in ersten Studien vielversprechende Ergebnisse zeigten. Erste Zulassungen durch die FDA sind für die Therapie des metastasierten/fortgeschrittenen Urothelkarzinoms bereits erfolgt. Andere zukünftige Optionen sind „maßgeschneiderte“ Therapiekonzepte, die auf der Molekularpathogenese des individuellen Patienten beruhen. Hier sind jedoch noch weitreichende präklinische Arbeiten erforderlich.
    Keywords: Urothelkarzinom ; Chemotherapie ; Immun-checkpoint blockade ; Zielgerichtete tumortherapie ; Prognostische faktoren ; Urothelial cancer ; Chemotherapy ; Immune checkpoint inhibition ; Targeted therapy ; Prognostic factors
    ISSN: 0001-7868
    E-ISSN: 1438-8820
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: German
    In: Uro-News, 9/2018, Vol.22(9), pp.28-32
    ISSN: 1432-9026
    E-ISSN: 2196-5676
    Source: Springer (via CrossRef)
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Translational Cancer Research, 02/2017, Vol.6(S1), pp.S221-S225
    ISSN: 2218676X
    E-ISSN: 22196803
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Urologic Oncology: Seminars and Original Investigations, June 2016, Vol.34(6), pp.256.e15-256.e21
    Description: Efficacy of palliative second-line treatment in patients suffering from advanced urothelial cancer (aUC) is limited. Accordingly, careful observation of patient-reported and treatment-related changes of quality of life (QoL) is mandatory. Therefore, we evaluated “typical” ailments and treatment related QoL changes in these patients. Results of the EORTC QLQ-C30 questionnaire were reviewed in 129 patients included in 2 prospective trials on paclitaxel-based treatment of cisplatin-resistant aUC (gemcitabine/paclitaxel: 102 patients [AB 20/99]; paclitaxel/everolimus: 27 patients [AB 35/09]). Eligible patients had completed EORTC QLQ-C30 questionnaire questionnaire before treatment start and available data on response. Global health status (QL), functional scales (FuSc) and symptom scales (SySc) were compared with published normative data for patients suffering from metastatic/recurrent cancers. Treatment related changes of QoL were evaluated. For statistical evaluation 2-way analysis of variance was used. A total of 87 patients were eligible (63 men and 24 women, median age = 65 [interquartile range: 60-71] y, AB 20/99: 63 patients [72%], AB 35/09: 24 patients [28%]). Compared with metastatic/recurrent cancers normative data, impaired emotional FuSc (−11.6 [95% CI:−21.0 to−2.1] points, 〈0.01) and higher pain SySc (+12.9 [CI: 3.7–22.1] points, 〈0.001) were the most relevant differences. QL and further FuSc/SySc were comparable. Pain SySc was significantly lower after 3 (−15.8 [CI:−31.4 to−0.7] points, 〈0.01] and 4 cycles (−13.6 [CI:−29.2–2.1] points, 〈0.05). Further changes of QL, FuSc or SySc during treatment were not observed. QL, FuSc, and SySc at baseline and during treatment did not differ between responders and nonresponders. Patients with aUC who received additional treatment demonstrated QoL changes similar to persons with other recurrent/metastatic cancers. Special emphasis should be attributed to pain and emotional problems. Despite treatment related side effects, patients did not report impairment of QoL.
    Keywords: Urothelial Carcinoma ; Chemotherapy ; Quality of Life ; Patient-Reported Outcomes ; Medicine
    ISSN: 1078-1439
    E-ISSN: 1873-2496
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: The Journal of Urology, April 2017, Vol.197(4), pp.e452-e453
    Description: To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.juro.2017.02.1080 Byline: Andreas Hiester Author Affiliation: Duesseldorf, Germany Article Note: (footnote) Source of Funding: none
    Keywords: Medicine
    ISSN: 0022-5347
    E-ISSN: 1527-3792
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: PLoS ONE, 2017, Vol.12(4)
    Description: Many long noncoding RNAs (lncRNAs) are deregulated in cancer and contribute to oncogenesis. In urothelial carcinoma (UC), several lncRNAs have been reported to be overexpressed and proposed as biomarkers. As most reports have not been confirmed independently in large tissue sets, we aimed to validate the diagnostic and prognostic value of lncRNA upregulation in independent cohorts of UC patients. Thus, expression of seven lncRNA candidates (GAS5, H19, linc-UBC1, MALAT1, ncRAN, TUG1, UCA1) was measured by RT-qPCR in cell lines and tissues and correlated to clinicopathological parameters including follow-up data (set 1: N n = 10; T n = 106). Additionally, publicly available TCGA data was investigated for differential expression in UC tissues (set 2: N n = 19; T n = 252,) and correlation to overall survival (OS). All proposed candidates tended to be upregulated in tumour tissues, with the exception of MALAT1, which was rather diminished in cancer tissues of both data sets. However, strong overexpression was generally limited to individual tumour tissues and statistically significant overexpression was only observed for UCA1, TUG1, ncRAN and linc-UBC1 in tissue set 2, but for no candidate in set 1. Altered expression of individual lncRNAs was associated with overall survival, but not consistently between both patient cohorts. Interestingly, lower expression of TUG1 in a subset of UC patients with muscle-invasive tumours was significantly correlated with worse OS in both cohorts. Further analysis revealed that tumours with low TUG1 expression are characterized by a basal-squamous-like subtype signature accounting for the association with poor outcome. In conclusion, our study demonstrates that overexpression of the candidate lncRNAs is found in many UC cases, but does not occur consistently and strongly enough to provide reliable diagnostic or prognostic value as an individual biomarker. Subtype-dependent expression patterns of lncRNAs like TUG1 could become useful to stratify patients by molecular subtype, thus aiding personalized treatments.
    Keywords: Research Article ; Biology And Life Sciences ; Biology And Life Sciences ; Medicine And Health Sciences ; Medicine And Health Sciences ; Research And Analysis Methods ; Physical Sciences ; Medicine And Health Sciences ; Medicine And Health Sciences ; Medicine And Health Sciences ; Medicine And Health Sciences ; Medicine And Health Sciences
    E-ISSN: 1932-6203
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Current Opinion in Urology, 2011, Vol.21(5), pp.434-439
    Description: PURPOSE OF REVIEW: Despite 5% advantage in 5-year overall survival, neoadjuvant chemotherapy may result in considerable overtreatment of bladder cancer patients because of the lack of response criteria. The reviewʼs purpose was to identify the criteria on which the selection of bladder cancer patients for neoadjuvant chemotherapy followed by radical cystectomy should be based. RECENT FINDINGS: About 30–40% of patients with metastatic bladder cancer are ineligible for platinum-based neoadjuvant chemotherapy because of renal impairment. Stratification based on the clinical tumor stage is likely to be biased by inappropriate preoperative staging. Differences in the response to neoadjuvant chemotherapy seem not to be predictable by histological subtype of bladder cancer. Future developments in radiological imaging, molecular cancer staging and response prediction aim to identify patients who will profit from neoadjuvant chemotherapy. SUMMARY: Patients considered for neoadjuvant chemotherapy should be eligible for cisplatinum-based regimens. To avoid overtreatment, preferably patients with nonorgan-confined and lymph-node disease should be treated by neoadjuvant chemotherapy. However, the possibility of staging error should be taken into account. Patients with limited metastatic disease may also profit from neoadjuvant chemotherapy followed by radical cystectomy with concomitant metastasectomy.
    Keywords: Combined Modality Therapy–Drug Therapy ; Cystectomy–Pathology ; Drug Therapy–Pathology ; Humans–Pathology ; Neoadjuvant Therapy–Pathology ; Neoplasm Staging–Pathology ; Patient Selection–Pathology ; Severity of Illness Index–Pathology ; Treatment Outcome–Pathology ; Urinary Bladder Neoplasms–Pathology;
    ISSN: 0963-0643
    E-ISSN: 14736586
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages